Startups Directory

At DAMATEC Labs (DAta, MAnagement and TEChnology) we believe in technology as a means to impact the world and improve people's quality of life. We support entrepreneurs, companies, and universities in taking their projects to the next level by assisting in venture building, product development, funding, and internationalization.

startups and spinoffs fail

Our main areas of impact in our partners: Increase in revenue. Increase in funding. Increase in valuation. Improvement of the team. Improvement or innovation in products and technologies. Enhancement in marketing and communication. Establishment of strategic partnerships. Other areas of interest.

300.000€

400.000€

Heuristik is a software solution to identify and manage patients combining fingerprints and AI

Patient identification errors, based on papers hospital made around 12,5% of identification errors with around 1B patient identification errors combining Europe and the US

Heuristik's solution is going to solve 99% of those identification errors, make healthcare process more agile and reduce 500kg of plastic per hospital (single use plastics)

3-5M €

3-5M €

Safeloc Systems is a deep-tech startup specialized in industrial-grade real-time location systems (RTLS) based on Ultra-Wideband (UWB) technology, designed to operate reliably in environments where conventional localization technologies fail. Safeloc’s solution delivers deterministic, sub-meter positioning in complex indoor settings characterized by metallic structures, multipath propagation, electromagnetic interference, and strict safety requirements. Unlike Wi-Fi, BLE, RFID, or vision-based systems, Safeloc is engineered for safety-critical use cases where localization errors are unacceptable and operational risk is non-negotiable. By combining proprietary UWB hardware, robust signal processing, and a controlled software stack with guaranteed latency and availability, Safeloc provides a level of reliability and predictability required for collision avoidance, hazard prevention, and mission-critical industrial operations.

Safeloc Systems’ technology solves the lack of reliable and precise real-time location information in safety-critical industrial environments where conventional positioning technologies are inaccurate or unstable. In complex indoor facilities, existing solutions based on Wi-Fi, Bluetooth, RFID, GNSS, or computer vision suffer from multipath effects, metallic interference, occlusions, or insufficient determinism, leading to unreliable positioning and unacceptable operational risk. Safeloc addresses this by providing deterministic, high-accuracy localization that enables the prevention of collisions between people and vehicles, uncontrolled access to hazardous zones, and unsafe proximity situations. In addition, the system solves inefficiencies caused by poor asset visibility, such as time lost searching for equipment, lack of traceability of work-in-progress, and limited data for process optimization. By delivering trustworthy location data with guaranteed performance, the product enables both safety enforcement and operational decision-making in environments where reliability is critical and failure is not an option.

Safeloc Systems’ technology has a direct and measurable impact on society by increasing safety, reliability, and efficiency in high-risk industrial environments. By enabling accurate and deterministic real-time localization, the system helps prevent workplace accidents involving people, vehicles, and hazardous areas, contributing to the reduction of injuries, fatalities, and long-term health risks in industrial operations. This directly improves worker protection and reinforces a culture of safety in sectors where risk exposure is inherently high. Beyond safety, the technology supports more efficient and sustainable industrial processes by reducing operational downtime, minimizing material losses, and enabling data-driven optimization of logistics and asset utilization. The availability of reliable spatial data also accelerates industrial digitalization, facilitating the adoption of advanced automation, digital twins, and intelligent decision systems. Overall, Safeloc’s solution contributes to safer workplaces, more resilient industrial infrastructure, and a more sustainable and competitive industrial ecosystem.

€1M

€2.5M

Scypios is an innovative company making significant advances in the treatment of myelin-related diseases, including severe conditions like multiple sclerosis, neuromyelitis optica, Charcot-Marie-Tooth disease, as well as neuropsychiatric and neurodegenerative diseases that also involve myelin loss. These diseases are characterized by demyelination, blockage, and oligodendrocyte death, leading to neuron death and resulting in sensory, motor, or cognitive impairment. Currently, myelin diseases affect approximately 200 million people globally, with an incidence of 2,500 cases per 100,000 people, a figure that continues to rise. Despite substantial efforts by the pharmaceutical industry, no treatment exists that can cure these diseases, as current drugs are unable to regenerate myelin. This challenge is largely due to the lack of adequate preclinical models that replicate the neurological pathophysiology of these neurodegenerative diseases. Scypios offers a breakthrough solution for pharmaceutical companies, CROs, and the scientific community by providing a unique animal model that accurately replicates the full neurological pathophysiology of myelin diseases. This model, validated and proven successful in concept tests, has been recognized by the academic field as a powerful tool for studying myelin-related diseases. Because our model reproduces the neurological characteristics of these diseases so comprehensively, it enhances the likelihood of drug discovery success, making the preclinical stage more applicable to clinical outcomes. Scypios’ animal model, protected by a European patent, is the product of over 15 years of research based on proprietary know-how safeguarded as an industrial secret. In a comparative analysis of available models based on reliability and availability, only our model and the classic model are accessible, with no close competitors able to replicate the neurological pathophysiology as accurately. Scypios’ ultimate goal is to provide the industry, CROs, and developers of treatments for myelin diseases with an animal model that faithfully reproduces these conditions’ pathophysiology. This model aims to enable the discovery of drugs capable of regenerating myelin and curing the over 200 million people suffering from these diseases worldwide.

Multiple sclerosis, mielin pathologies, Preclinical Drug Screening Service, Myelinopathies

Myelin diseases, such as multiple sclerosis, not only cause substantial human suffering but also generate a high economic burden, with an estimated healthcare cost of approximately €40,000 per patient per year in Spain. These pathologies profoundly affect patients’ lives and their social environment and represent one of the leading causes of disability in young adults. The development of effective treatments could significantly reduce the costs associated with patient care, alleviating the economic and social burden on families and the healthcare system. From a business perspective, we offer the pharmaceutical industry an innovative tool for drug screening, which will facilitate the success of clinical trials in myelin-related disorders (Patent Number: 20 382 869.4). In this way, the project aims to promote technological development and competitiveness in the biotechnology sector, generating highly qualified employment and providing training opportunities in areas such as biomedicine and regenerative medicine. This initiative is supported by the UAM Foundation and the Foundation for Knowledge of the Community of Madrid. Overall, the outcomes of this project will not only advance the treatment of myelin diseases but will also have a positive societal impact by improving patients’ quality of life, fostering technological innovation, and contributing to job creation.

500.000 €

1.000.000 €

Reinforce3D is a deep-tech company industrializing CFIP – Continuous Fiber Injection Process, a patented technology that transforms any polymer or metal part into a lightweight, high-performance composite structure. Unlike traditional composites or in-process fiber 3D printing, CFIP injects continuous fibers inside a finished part, delivering composite-level strength without molds, autoclaves, or manual lay-up. The company has already commercialized its first product (Delta) with systems installed across Europe and the USA, validating applications in sporting goods, orthotics & prosthetics, UAV/defense, and industrial tooling. Reinforce3D is now developing Delta Modular, a fully automated CFIP platform for industrial-scale manufacturing. By enabling stronger, lighter, and more sustainable parts, Reinforce3D is positioned to become the global standard for structural reinforcement in digital and advanced manufacturing.

1. Composites are slow, manual, and expensive. Reinforcement today depends on molds, autoclaves, and manual lay-up, making high-performance parts costly and unscalable. 2. Additive Manufacturing lacks structural performance. 3D-printed parts provide less than 25% of composite strength, preventing their use in load-bearing applications across aerospace, UAVs, medical devices, and mobility. 3. Reinforcement is the missing link in digital manufacturing. While design and production are fully digital, reinforcement remains manual, blocking automated, mold-free, rapid iteration workflows. 4. Lightweight, strong parts are needed across industries. Drones, EVs, robotics, and sports depend on lighter, stronger structures but current manufacturing cannot deliver performance without high cost. 5. Complex geometries and multi-material parts cannot be reinforced. Existing technologies cannot place continuous fibers inside internal cavities or complex shapes, limiting design freedom and performance. CFIP injects continuous fibers inside any manufactured part—after it is made—creating composite-level strength without molds, autoclaves, or manual lay-up. This post-process reinforcement transforms weak or complex components into lightweight, high-performance structures, works with any material or geometry, and integrates into fully digital, automated workflows.

1. More sustainable manufacturing. CFIP eliminates molds, reduces composite waste by 25–50%, and enables lighter products that consume less energy. This supports greener mobility, longer-range drones, lower-emission logistics, and reduced material usage across industries. 2. Safer, more accessible medical devices. By reinforcing patient-specific orthoses and prostheses, CFIP enables stronger, lighter, and more comfortable medical devices. This improves patient mobility, reduces failure risk, and lowers production time for personalized care. 3. Enabling cleaner, more efficient transportation. Lightweight structural parts directly increase energy efficiency in mobility, aerospace, robotics, drones, and autonomous systems. This leads to lower operational costs and reduced environmental footprint. 4. Democratization of advanced materials. CFIP removes the dependency on expensive composite tooling and skilled manual labor. It enables small and medium manufacturers to produce high-performance structures locally, accelerating industrial innovation. 5. Acceleration of digital and local production. By embedding reinforcement into fully automated digital workflows, CFIP enables rapid iteration and cost-efficient local manufacturing. This strengthens regional supply chains and reduces dependence on offshore composite production.

5M€

5M€

Peptide Solution Targeting Metabolic Liver Disease

LIFESOMIX is developing a first-in-class therapy for metabolic dysfunction-associated steatotic liver disease (MASLD) formerly known as non-alcoholic fatty liver disease (NAFLD) and its severe complication, metabolic dysfunction-associated steatohepatitis (MASH or NASH). MASLD/MASH is a major contributor to cardiovascular risk in patients with metabolic diseases and the leading cause of liver-related morbidity and mortality, often progressing to severe fibrosis, cirrhosis and even liver cancer. MASLD affects approximately 25.2% of the global population, with around 20% of cases progressing to MASH. Among MASH patients, 30-40% develop fibrosis, and 20% progress to cirrhosis. Besides lifestyle changes and treating comorbidities such as obesity and diabetes, effective treatments for MASLD remain limited, highlighting an urgent need for new therapeutic options.

We offer an innovative peptidomimetic approach based on a unique domain in SOCS1 protein to inhibit JAK activity and regulate lipid metabolism, inflammation and fibrosis-key drivers of MASLD/MASH progression. Lead compound and derivatives, patented for use in liver diseases, have shown efficacy in vitro and in vivo in well-established MASLD mouse models, successfully reducing hepatic damage (~40% decrease) and restoring the gene expression balance. This proof-of-concept supports preclinical development as future treatment for NAFLD patients. We provide an alternative for steatosis, MASH, and fibrosis, with the potential to reverse hepatic fibrosis associated with other diseases (a condition with no effective treatment). By addressing a critical unmet need, our technology aims to improve patient outcomes and quality of life for millions affected by liver diseases.

We are seeking an initial investment of €0.5M in a pre-seed round to maintain the patent, start API manufacturing, advance formulation, and conduct key analytical studies. Further, in a seed round, we will continue these activities and begin the non-clinical regulatory process. With additional rounds, our goal is to complete regulatory development and start early phases in humans once authorized by the AEMPS. This strategy ensures project's progress and long-term commercial viability.

The initial investment round totals €3M (pre-seed €0.5M; seed €2.5M) to support API manufacturing, formulation and early non-clinical regulatory activities, with later rounds planned to advance Phase I and IIa clinical trials.

WAPTEL (Wave and Particle Engineering Solutions) is a private fabless technology company based in Madrid that specializes in the design and development of high-tech photonic and electronic solutions, products, and services. Its capabilities span from concept and physical simulation of structures and devices to final system characterization, including manufacturing process definition and integrated circuit or structure design. The company conducts R&D in semiconductor technologies (especially III-V, lithium niobate and silicon), photonics, quantum devices, and wireless optical communications, and it possesses in-house prototyping facilities for advanced device development. WAPTEL’s work applies across consumer information and communication technologies as well as specialized areas such as aerospace, health, energy, security, and defense.

This technology addresses these main problems: • Limits of direct laser modulation at high speed • Costly/inefficient optical coupling in integrated waveguide modulators • Need for “natural” out-of-plane coupling in certain use cases • Possibility of using high-bandwith modulation for large area devices

This technology can improve high-speed optical communications while reducing energy consumption, enabling more efficient networks and data systems.

1 M€

The total size of the investment round is planned to be approximately 1M€.

Calpech is a nanotechnology startup that transforms agricultural waste into iron nanoparticles for biogas optimization, environmental remediation, and sustainable energy applications, bridging scientific innovation and industrial deployment.

Biogas plants suffer from low efficiency, process instability, and high contaminant management costs, while agricultural waste remains underutilized. Calpech addresses both by improving biogas performance and valorizing agricultural residues through nanotechnology.

Calpech’s technology accelerates the energy transition by increasing renewable biogas efficiency, reducing emissions and contaminants, and converting agricultural waste into valuable resources, supporting a more sustainable and circular economy.

2.000.000€

300.000€

Making great hearing solutions accessible to everyone.

Hearing impairment.

Make hearing aids solutions accessible to everyone.

100K Euros

200K Euros

A new, clearer way to understand and own your health.

Most people have access to health data, but lack the clarity, context, and guidance to understand what it means, how it connects, and how it impacts their present and future health. As a result, health indicators feel fragmented, conversations with healthcare professionals are often reactive or unproductive, and people remain disengaged from their own health until problems arise.

Empower people to engage with their health holistically and have more informed, effective conversations with healthcare professionals.

N/A

N/A

Re-thinking college education and classrooms.

Higher education is struggling to keep pace with how learning is evolving. The way knowledge is taught, explored, and internalised no longer fully aligns with how students engage with information today, creating growing tension between formal learning structures and real learning behaviour.

Sophai contributes to a gradual shift in how society relates to knowledge, encouraging more thoughtful learning, better judgment, and a more conscious use of AI in everyday decisions.

100k€

200k€

Labfit is a CDRO and Pharmapoli is a CDMO. Together the two facilities cover the complete value chain for cosmetics and medical devices from product development, lab and regulatory characterization to industrial production. Labfit is a GLP and ISO13485 lab and Pharnapoli is a GMP cosmetics and ISO13485 industrial facility.

High quality Services and industrial production.

Better products and services.

N/A

N/A

We invent and develop sensors for clinical and aesthetics medicine

We have two products. One sensors that improves tattoo removal processes and a hearable (earbud) that is able to retrieve the heart rate

On one hand, tattoos have become mainstream. Safe tattoo removal methods are strongly demanded by society. On the other hand, wearables (and in particular hearables) are reshaping the healthcare paradigm, switching from a reactive medicine approach to a more efficent proactive scheme.

300.000€

300.000€

Porous Energy is a technological company dedicated to developing next-generation electrodes for high-energy-density, low-cost supercapacitors. Its patented microfluidic 3D-printing technology, applied to covalent organic frameworks (COFs) and graphene, enables the fabrication of customizable electrodes with capacitances of up to 233 F/g. As a result, Porous Energy combines innovation, efficiency, and sustainability to drive the next generation of energy storage solutions.

The transition to renewable energy and electric mobility is fundamentally limited by current energy storage technologies. While supercapacitors are uniquely positioned to bridge the gap between conventional capacitors and batteries existing solutions still face major limitations. Today’s supercapacitors rely on expensive materials, costly manufacturing processes, and metal-based components, while conventional carbon electrodes fail to deliver sufficient energy density. In addition, most available solutions lack the flexibility to be customized for specific applications. Our technology addresses these challenges by enabling high-performance, cost-efficient, and customizable supercapacitor electrodes, unlocking the full potential of supercapacitors for next-generation energy storage systems.

Our technology supports the energy transition by enabling efficient, lightweight, and environmentally friendly supercapacitor electrodes. By reducing weight and material use in high-power energy storage systems, it enables more sustainable solutions in applications where weight is critical, such as drones, aerospace, defense, and automotive safety systems. This contributes directly to improved energy efficiency, lower environmental impact, and the objectives of the UN 2030 Agenda.

750000€

200000€ closed seed round

Our technology combines systems chemistry, reaction networks, and high-throughput analysis for the discovery of new pharmacologically active compounds.

Discovery of bioactive compounds through the use of microfluidic flow reactors and chemical reaction networks

Our technology will be unique in the chemical and pharma sectors, and may save a lot of time and resources in high-throughput campaigns for the discovery of drug candidates at the preclinical stage.

300 k€

Estimated € 1–1.3 million